A trial to find out how well CVHNLC works at different dose levels and how safe it is in combination with pembrolizumab in patients with lung cancer that cannot be completely cured.

Status

Not yet recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519651-28-00

Acronym

CV-HNLC-001

Enrollment

Registered

2025-06-03

Start date

Unknown

Completion date

Unknown

Last updated

2025-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic squamous non-small cell lung cancer

None listed

Sex/Gender

All

Age

18 Years to No maximum

France, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026